The Reference Dose (RfD) for chronic oral exposures is 0.005 mg/kg/day for both selenium and selenious acid (U.S. EPA, 1992a, 1992b). The subchronic RfDs for these compounds are the same as the chronic RfDs (U.S. EPA, 1992c).
In humans, inhalation of selenium or selenium compounds primarily affects the respiratory system. Dusts of elemental selenium and selenium dioxide can cause irritation of the skin and mucous membranes of the nose and throat, coughing, nosebleed, loss of sense of smell, dyspnea, bronchial spasms, bronchitis, and chemical pneumonia (Clinton, 1947; Hamilton, 1949). Other signs and symptoms following acute inhalation exposures include lacrimation, irritation and redness of the eyes, gastrointestinal distress (nausea and vomiting), depressed blood pressure, elevated pulse rate, headaches, dizziness, and malaise (ATSDR, 1989). In animals, acute inhalation exposures also result in severe respiratory effects including edema, hemorrhage, and interstitial pneumonitis (Hall et al., 1951; Dudley and Miller, 1937) as well as in splenic damage (congestion, fissuring red pulp, and increased polymorphonuclear leukocytes) and liver congestion and mild central atrophy (Hall et al., 1951). Information on toxicity of selenium in humans and animals following chronic inhalation exposures is not available, and subchronic and chronic inhalation Reference Concentrations have not been derived.